Intensity-modulated radiation therapy and doxorubicin in thyroid cancer: A prospective phase 2 trial.

ABSTRACT:

Background

The use of external-beam radiotherapy for locally advanced nonanaplastic thyroid cancer remains controversial. This prospective study evaluated the efficacy and tolerability of intensity-modulated radiation therapy (IMRT) with or without concurrent chemotherapy in patients with locally advanced thyroid cancer.

Methods

The authors conducted a nonrandomized phase 2 trial of IMRT with or without concurrent doxorubicin in patients with gross residual or unresectable nonanaplastic thyroid carcinoma (ClinicalTrials.gov identifier NCT01882816). The primary end point was 2-year locoregional progression-free survival (PFS). Secondary end points included overall survival (OS), safety, patient-reported outcomes, and functional outcomes.

Results

Twenty-seven patients w

SUBMITTER: Romesser PB 

PROVIDER: S-EPMC9455581 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature